Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Desloratadine + betamethasone** is an oral fixed-dose anti-allergic combination of desloratadine, a second-generation peripheral histamine H1-receptor inverse agonist, and betamethasone, a synthetic glucocorticoid receptor agonist with anti-inflammatory and immunosuppressive activity. It is marketed in several countries as products including Frenaler Cort and Oradus Beta for severe allergic and inflammatory conditions, including allergic rhinitis, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, allergic conjunctivitis, and food- or medicine-associated allergic reactions. Available products include film-coated tablets and oral liquid formulations; tablet products commonly contain desloratadine 5 mg plus betamethasone 0.6 mg. ([pharmaline.com.lb](https://www.pharmaline.com.lb/pharmaline/english/products/oradus-beta))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desloratadine + betamethasone.